The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: immunogenic fusion proteins. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Innovation in pharma: immunogenic fusion proteins

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

80+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 668,000 patents, there are 80+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Phenotypic drug screening, antibody-drug conjugates, and polysaccharide-protein conjugate vaccines are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are drug delivery nanoparticles and antibody encoding polynucleotide libraries, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Immunogenic fusion proteins is a key innovation area in the pharmaceutical industry

Immunogenic fusion proteins are molecules formed by the fusion of two or more protein sequences, whereby at least one of which is an antigenic or immunogenic sequence. These proteins are designed to stimulate an immune response in the body, either as a therapeutic agent for treating disease or as a vaccination strategy for preventing disease.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 260+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of immunogenic fusion proteins.

Key players in immunogenic fusion proteins – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to immunogenic fusion proteins

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
GSK 1276 Unlock Company Profile
Johnson & Johnson 296 Unlock Company Profile
Sanofi 186 Unlock Company Profile
Pfizer 179 Unlock Company Profile
Zoetis 144 Unlock Company Profile
Novartis 141 Unlock Company Profile
C. H. Boehringer Sohn 128 Unlock Company Profile
Qu Biologics 105 Unlock Company Profile
Sanaria 89 Unlock Company Profile
Molecular Templates 86 Unlock Company Profile
U.S. Department of Defence 78 Unlock Company Profile
Children's Medical Center 75 Unlock Company Profile
Vaximm 71 Unlock Company Profile
Inovio Pharmaceuticals 69 Unlock Company Profile
Bharat Biotech 68 Unlock Company Profile
Otsuka 61 Unlock Company Profile
Merck 54 Unlock Company Profile
Adjuvance Technologies 50 Unlock Company Profile
Sequoia Vaccines 50 Unlock Company Profile
Zydus Lifesciences 50 Unlock Company Profile
Gilead Sciences 48 Unlock Company Profile
Curevac 48 Unlock Company Profile
Artificial Cell Technologies 46 Unlock Company Profile
Sentinext Therapeutics Sdn Bhd 44 Unlock Company Profile
Centre National de la Recherche Scientifique 42 Unlock Company Profile
Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung 41 Unlock Company Profile
Scandinavian Biopharma 36 Unlock Company Profile
Panacea Biotec 35 Unlock Company Profile
X4 Pharmaceuticals 33 Unlock Company Profile
VLP Therapeutics 33 Unlock Company Profile
Regeneron Pharmaceuticals 33 Unlock Company Profile
Optimus 30 Unlock Company Profile
Leidos 29 Unlock Company Profile
Takeda Pharmaceutical 29 Unlock Company Profile
Eurofins Scientific 27 Unlock Company Profile
The Henry M Jackson Foundation for the Advancement of Military Medicine 27 Unlock Company Profile
The Cleveland Clinic Foundation 26 Unlock Company Profile
Meiji 26 Unlock Company Profile
Shin Nippon Biomedical Laboratories 22 Unlock Company Profile
Vaxxinova 22 Unlock Company Profile
Prokarium 20 Unlock Company Profile
Rhode Island Hospital 20 Unlock Company Profile
Eidgenossische Technische Hochschule Zurich 20 Unlock Company Profile
Morishita Jintan 20 Unlock Company Profile
United States Army Reserve 20 Unlock Company Profile
CJ 19 Unlock Company Profile
Henry M. Jackson Foundation for the Advancement of Military Medicine 18 Unlock Company Profile
Vir Biotechnology 18 Unlock Company Profile
Nationwide Children's Hospital 17 Unlock Company Profile
Vac-4-All 17 Unlock Company Profile

Source: GlobalData Patent Analytics

GSK is one of the leading patent filers in immunogenic fusion proteins. The company is exploring several fusion proteins in the immunogenic space. One such fusion protein is pabinafusp alfa, which is being developed in collaboration with JCR Pharmaceuticals. The company is also developing other drugs with several other companies.

In terms of application diversity, Molecular Templates leads the pack, while Nationwide Children's Hospital and X4 Pharmaceuticals stood in second and third positions, respectively. By means of geographic reach, Molecular Templates held the top position. followed by Gilead Sciences and X4 Pharmaceuticals.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.